drugset / Trial / NCT01515410

Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations

NCT01515410

Phase 2 Completed 34 enrolled Depomed
RandomizedCrossoverOpen-labelTreatment

Summary

The primary objective of this study is to explore the efficacy and tolerability of DM-1992 compared to a standard carbidopa/Levodopa Immediate-Release (CD/LD IR) tablet (Sinemet IR) as measured by: * "ON" time with no dyskinesia or non-troublesome dyskinesia * "OFF" time

Timeline

Start
2012-01
Primary completion
2012-09
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown 25 mg
Subject Carbidopa Unknown 72.5 mg
Subject Levodopa Small molecule 100 mg
Subject Levodopa Small molecule 230 mg

Indications